January 20, 2021 -- Immuno-oncology firm Kiromic BioPharma has completed and certified its good manufacturing practice (GMP) facility in Houston, TX. The facility will be used to produce off-the-shelf allogenic chimeric antigen receptor (CAR) products for upcoming trials targeting ovarian cancer.
The company's gamma-delta T cells (GDT cells) are more efficient at killing tumor cells and more resistant to tumor escape mechanisms in solid tumors than more traditionally used alpha-beta T cells. GDT cells can be produced using blood from healthy donors in a process called allogenic cell transfer, according to the company. Furthermore, GDT cells only target tumor cells for which they have been engineered.
Copyright © 2021 scienceboard.net